Roche has revealed that it’s closed it’s $1.9 billion acquisition of digital healthcare technology company Flatiron Health.

The New York city-based firm designs and develops oncology-specific electronic health record software, and supports in curating and developing real-world evidence for cancer research, writes Mass Device

Under the acquisition deal, Flatiron will continue to operate as a separate legal entity and maintain its independence, as well as its business model, partnerships, and existing objectives.

Roche believes that the acquisition will allow both companies to accelerate their development of data-driven personalised healthcare products in the oncology field. 

Materials provided by Roche. Note: Content may be edited for style and length.